On May 19, 2026 Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, reported data to be featured at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place May 29 – June 2, 2026 in Chicago, IL.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation details are as follows:
Date & Time: Monday, June 1
Session Type: Poster
Session Title: Sarcoma
Poster Number: 376b
Title: A phase 1/2, multi-center, open-label study to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary anti-neoplastic activity of LNTH-2403, a LRRC15-targeted 177lutetium-labeled monoclonal antibody, in patients with relapsed/refractory osteosarcoma.
Presenter: Noah Federman, UCLA Jonsson Comprehensive Cancer Center, UCLA David Geffen School of Medicine, Los Angeles, CA
Session Type: Publication Only
Session Title: Publication Only: Genitourinary Cancer—Prostate, Testicular, and Penile
Title: Real-world use of piflufolastat F 18 and imaging-associated treatment patterns in early-stage prostate cancer.
First Author: Emma Billmyer, The Analysis Group, Boston, MA
Abstract Number: e17126
(Press release, Lantheus, MAY 19, 2026, View Source [SID1234665862])